HYFT MindWalk Therapeutics: Enterprise Value to EBITDA Ratio

ipatherapeutics.com (HYFT) - corporate logo

Despite a talent shortage and the competition for rare biochemist-programmers, MindWalk Holdings (HYFT) continues to grow steadily. This chart on GURU.Markets shows an EV/EBITDA of 0.00. The business relies on a SaaS model for biodata analysis, which ensures high margins. The application of AI in drug development eliminates physical research costs, optimizing therapeutic supply chains.

MindWalk Holdings, Inc. - HYFT Business Value to Operating Income Before Depreciation (period 11/23/2025 - 11/16/2026)

Comprehensive metric breakdowns and analytics for MindWalk Holdings, Inc. (HYFT)

Analysis of all company metrics:ipatherapeutics.com HYFT
Original product of MindWalk Holdings Inc.

For a defensive portfolio, accounting for Enterprise Value (EV) relative to EBITDA is critical, as it allows for an assessment of the real value of assets amid changing borrowing costs. Given the volatile revenues of MindWalk Holdings (HYFT) and the absence of stable cash flow, the EV/EBITDA multiple for this capital-intensive business reveals a risk of equity overvaluation relative to its current ability to act as a cash generator.

Analysis of competing companies

Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Theravance Biopharma Inc (TBPH)|AQST (aquestive.com) - EV/EBITDA Multiple|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|Tonix Pharmaceuticals Holding Corp. - Enterprise Value to Operating Income Before Depreciation|China SXT Pharmaceuticals - Enterprise Value to EBITDA Ratio|EPRX: Enterprise Value to Operating Income Before Depreciation|BHST: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Invizyne|Oramed Pharmaceuticals Inc. (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ENTX (Entera Bio Ltd) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to Operating Income Before Depreciation CPIX (Cumberland Pharmaceuticals Inc.)|EV/EBITDA Multiple QNTM|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Corporation|EV/EBITDA Multiple TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|SNYR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio